An Open-label Study to Evaluate the Long-Term Safety and Tolerability of Iptacopan in Patients With Complement Mediated Diseases.
An Open-label, Single-arm, Multicenter Roll-over Extension Program (REP) to Characterize the Long-term Safety and Tolerability of Iptacopan (LNP023) in Patients Who Have Completed a Clinical Trial (Parent Study) in the Iptacopan Pediatric Program
The purpose of this single-arm, multicenter, Phase IIIb roll-over extension study is to assess the long-term safety, tolerability, and efficacy of iptacopan in participants with complement mediated diseases.
Panoramica dello studio
Stato
Stato
Condizioni
Condizioni
Intervento / Trattamento
Intervento / Trattamento
Descrizione dettagliata
This is a Phase IIIb, multicenter, open-label, single-arm roll-over extension study designed to evaluate the long-term safety, tolerability, and efficacy of iptacopan in participants with complement-mediated diseases who have completed a preceding Novartis-sponsored pediatric clinical trial with iptacopan and who, in the opinion of the investigator, continue to derive clinical benefit from treatment. The study will provide post-trial access to iptacopan while continuing to collect long-term safety and efficacy data.
Eligible participants who have completed a pediatric iptacopan parent study will continue to receive open-label iptacopan in this extension study.
Treatment may continue for up to 3 years following the study last patient first visit, or until iptacopan becomes commercially available and/or reimbursed according to local post-trial access requirements, whichever occurs first.
Tipo di studio
Tipo di studio
Iscrizione (Stimato)
Iscrizione
Fase
Fase
- Fase 3
Accesso esteso
Accesso esteso
A disposizione
- Disponibile: l'accesso esteso è attualmente disponibile per questo trattamento sperimentale e i pazienti che non partecipano allo studio clinico potrebbero essere in grado di accedere al farmaco, al biologico o al dispositivo medico in fase di studio.
- Non più disponibile: l'accesso esteso era disponibile per questo intervento in precedenza, ma non è attualmente disponibile e non sarà disponibile in futuro.
- Temporaneamente non disponibile: l'accesso esteso non è attualmente disponibile per questo intervento, ma dovrebbe esserlo in futuro.
- Approvato per il marketing: l'intervento è stato approvato dalla Food and Drug Administration degli Stati Uniti per l'uso da parte del pubblico.
Contatti e Sedi
Contatto studio
Contatto studio
- Nome: Novartis Pharmaceuticals
- Numero di telefono: 1-888-669-6682
- Email: novartis.email@novartis.com
Backup dei contatti dello studio
- Nome: Novartis Pharmaceuticals
- Numero di telefono: +41613241111
- Email: novartis.email@novartis.com
Criteri di partecipazione
Criteri di ammissibilità
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
Participants eligible for inclusion in this study must meet all of the following criteria:
- Signed informed consent by parent(s)/legal guardian(s) for the patient must be obtained before enrolling in the roll-over study and receiving study medication. A consent or assent may also be required for some patients depending upon their age and local requirements.
- Male and female participant and has completed the treatment period in the Novartis sponsored pediatric study with iptacopan in any complement mediated disease (e.g., CLNP023I12201 or CLNP023G12301) on study drug.
- Willingness and ability to comply with scheduled visits, treatment plans and any other study procedures.
- Prior vaccinations against Neisseria meningitidis, Streptococcus pneumoniae and Haemophilus influenzae infections should be up to date (i.e. any boosters required administered according to local regulations).
- Per investigator's clinical judgement, the patient may benefit from continued treatment with iptacopan and has been clinically stable on iptacopan prior to enrollment in this extension study.
Exclusion Criteria:
- Any comorbidity or medical condition (including but not limited to any active systemic bacterial, viral or fungal infection or malignancy) that, in the opinion of the investigator, could put the subject at increased risk or potentially confound study data.
- History of recurrent invasive infections caused by encapsulated organisms, such as Neisseria meningitidis, Streptococcus pneumoniae or Haemophilus influenzae.
- Women of child-bearing potential, defined as all women physiologically capable of becoming pregnant from menarche until becoming post-menopausal, unless they are using effective methods of contraception during dosing of study treatment and for 1 week after stopping study treatment. Effective contraception methods include:
- Total abstinence (when this is in line with the preferred and usual lifestyle of the participant). Note that periodic abstinence (e.g., calendar, ovulation, symptothermal, post ovulation methods) and withdrawal are not acceptable methods of contraception.
- Bilateral oophorectomy with or without hysterectomy, total hysterectomy, or bilateral salpingectomy at least 6 weeks before taking study treatment. In case of oophorectomy alone, only when the reproductive status of the woman has been confirmed by follow up hormone level assessment are they not considered to be of childbearing potential.
- Bilateral tubal occlusion, bilateral tubal ligation (at least 6 weeks before taking study treatment).
- Barrier methods of contraception: condom or occlusive cap (e.g., diaphragm or cervical/vault caps). For the UK: with spermicidal foam/gel/film/cream/vaginal suppository.
- Use of hormonal contraception methods:
- Combined (estrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation; oral, intravaginal or transdermal.
- Progestogen-only hormonal contraception associated with inhibition of ovulation: oral, injectable or implantable.
- Intrauterine device (IUD) or intrauterine hormone-releasing system (IUS).
Other protocol-defined inclusion/exclusion criteria may apply.
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: N / A
- Modello interventistico: Assegnazione di gruppo singolo
- Mascheramento: Nessuno (etichetta aperta)
Numero di armi
Armi e interventi
Gruppo di partecipanti / ArmGruppo di partecipanti / Arm |
Intervento / TrattamentoIntervento / Trattamento |
|---|---|
|
Sperimentale: Iptacopan
Participants with complement-mediated diseases who have completed a preceding Novartis-sponsored pediatric clinical trial with iptacopan and who continue to derive clinical benefit from treatment will receive open-label iptacopan. Participants >12 years of age will receive iptacopan 200 mg twice daily, and participants aged 2 to <12 years will receive weight-based dosing. |
Participants >12 years of age will receive iptacopan 200 mg twice daily, and participants aged 2 to <12 years will receive weight-based dosing.
Altri nomi:
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Number of participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)
Lasso di tempo: From Day 1 through End of Treatment (EOT)/End of Study (EOS), up to approximately 3 years
|
Number of participants with AEs, SAEs and major adverse vascular events (MAVE) including abnormal cardiovascular parameters, safety laboratory parameters and vital signs qualifying and reported as AEs. |
From Day 1 through End of Treatment (EOT)/End of Study (EOS), up to approximately 3 years
|
Misure di risultato secondarie
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Proportion of participants maintaining stable hemoglobin levels - PNH Indication only
Lasso di tempo: From baseline through EOT/EOS, up to approximately 3 years
|
Proportion of participants with paroxysmal nocturnal hemoglobinuria (PNH) maintaining stable hemoglobin (Hb) levels in absence of red blood cell transfusions. Stable Hb is defined as no more than a ≥2 g/dL decrease from baseline. |
From baseline through EOT/EOS, up to approximately 3 years
|
|
Proportion of participants maintaining sustained hemoglobin levels ≥10 g/dL and ≥12 g/dL - PNH Indication only
Lasso di tempo: Yearly through EOT/EOS, up to approximately 3 years
|
Proportion of participants with PNH maintaining sustained hemoglobin levels ≥10 g/dL and ≥12 g/dL in the absence of red blood cell transfusions |
Yearly through EOT/EOS, up to approximately 3 years
|
|
Proportion of participants with Hb levels ≥10 g/dL and ≥12 g/dL and LDH ≤1.5 ULN - PNH Indication only
Lasso di tempo: From Day 1 through EOT/EOS, up to approximately 3 years
|
Proportion of participants with PNH achieving hemoglobin (Hb) levels ≥10 g/dL and ≥12 g/dL and lactate dehydrogenase (LDH) ≤1.5 times the upper limit of normal (ULN). |
From Day 1 through EOT/EOS, up to approximately 3 years
|
|
Rate of Breakthrough Hemolysis - PNH Indication only
Lasso di tempo: From baseline through End of Treatment/End of Study (up to approximately 3 years)
|
Breakthrough hemolysis events in participants with paroxysmal nocturnal hemoglobinuria (PNH). Clinical breakthrough hemolysis is defined based on protocol-specified clinical and laboratory criteria, including evidence of intravascular hemolysis and associated clinical signs/symptoms. The endpoint will be summarized as occurrences per year |
From baseline through End of Treatment/End of Study (up to approximately 3 years)
|
|
Log-transformed ratio to baseline in Urinary Protein-to-Creatinine Ratio (UPCR) - IgAN indication only
Lasso di tempo: Baseline and up to approximately 3 years
|
Log-transformed ratio to baseline in UPCR measured using first morning void (FMV) urine samples in participants with immunoglobulin A nephropathy (IgAN). |
Baseline and up to approximately 3 years
|
|
Change from baseline in estimated Glomerular Filtration Rate (eGFR) - IgAN indication only
Lasso di tempo: Baseline and up to approximately 3 years
|
Change from baseline in estimated glomerular filtration rate (eGFR) in participants with IgAN. |
Baseline and up to approximately 3 years
|
|
Proportion of participants achieving UPCR <0.5 g/g - IgAN indication only
Lasso di tempo: At EOT/EOS, up to approximately 3 years
|
Proportion of participants with IgAN achieving urinary protein-to-creatinine ratio (UPCR) <0.5 g/g. |
At EOT/EOS, up to approximately 3 years
|
Collaboratori e investigatori
Sponsor
Sponsor
Investigatori
Investigatori
- Direttore dello studio: Novartis Pharmaceuticals, Novartis Pharmaceuticals
Studiare le date dei record
Studia le date principali
Inizio studio (Stimato)
Inizio studio
Completamento primario (Stimato)
Completamento primario
Completamento dello studio (Stimato)
Completamento dello studio
Date di iscrizione allo studio
Primo inviato
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Primo Inserito
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento pubblicato
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
- Malattie urogenitali
- Malattie urogenitali maschili
- Malattie renali
- Malattie urologiche
- Malattie urogenitali femminili
- Malattie urogenitali femminili e complicanze della gravidanza
- Malattie autoimmuni
- Malattie del sistema immunitario
- Disturbi della minzione
- Manifestazioni urologiche
- Malattie ematologiche
- Glomerulonefrite
- Nefrite
- Condizioni patologiche, segni e sintomi
- Segni e sintomi
- Malattie emiche e linfatiche
- Anemia
- Glomerulonefrite, IGA
- Proteinuria
- iptacopan
Altri numeri di identificazione dello studio
Altri numeri di identificazione dello studio
- CLNP023I12001B
- 2026-525677-39 (Numero EudraCT)
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Descrizione del piano IPD
Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.
This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .